ReviewStem cells translational medicine2019
Concise Review: Skeletal Muscle as a Delivery Route for Mesenchymal Stromal Cells.
Review in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.Stem cell research & therapy · 2021Pooled it
- A Phase 1 clinical trial to evaluate the safety and tolerability of CLZ-2002 for the treatment of patients with Charcot-Marie-Tooth disease type 1.Stem cells translational medicine · 2026Article
- Musculoskeletal ultrasound-guided cellular therapy: Current applications and future directions in skeletal muscle regeneration.Iranian journal of basic medical sciences · 2026Review
- Preclinical efficacy of adipose-derived cell therapies for the treatment of myositis.Stem cells translational medicine · 2025Article
- Stem cell therapies in the clinic.Bioengineering & translational medicine · 2025Review
- Intraosseous Delivery of Mesenchymal Stem Cells for the Treatment of Bone and Hematological Diseases.Current issues in molecular biology · 2024Review
- The comparison of adipose-derived stromal cells (ADSCs) delivery method in a murine model of hindlimb ischemia.Stem cell research & therapy · 2024Article
- Stromal vascular fraction in the treatment of myositis.Cell death discovery · 2023Review
- Soluble components from mesenchymal stromal cell processing exert anti-inflammatory effects and facilitate ischemic muscle regeneration.Cytotherapy · 2023Article
- Single-cell sequencing deconvolutes cellular responses to exercise in human skeletal muscle.Communications biology · 2022Article
- Assessment of endothelial colony forming cells delivery routes in a murine model of critical limb threatening ischemia using an optimized cell tracking approach.Stem cell research & therapy · 2022Article
- Article
- Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much?Cytotherapy · 2021Review
- Biodistribution of Mesenchymal Stromal Cells after Administration in Animal Models and Humans: A Systematic Review.Journal of clinical medicine · 2021Review
- In Vivo Printing of Nanoenabled Scaffolds for the Treatment of Skeletal Muscle Injuries.Advanced healthcare materials · 2021Article
- Stem Cell Therapy for Neurodegenerative Diseases: How Do Stem Cells Bypass the Blood-Brain Barrier and Home to the Brain?Stem cells international · 2020Review
- Perinatal Cells: A Promising COVID-19 Therapy?Frontiers in bioengineering and biotechnology · 2020Review
- MicroRNAs and long noncoding RNAs: new regulators in cell fate determination of mesenchymal stem cells.RSC advances · 2019Review
- Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stromal cells (MSCs) have demonstrated extensive capacity to modulate a catabolic microenvironment toward tissue repair. The fate, biodistribution, and dwell time of the in vivo delivered MSCs largely depend on the choice of the cell delivery route. Intramuscular (IM) delivery of MSCs is clinically safe and has been used for the effective treatment of local pathologies. Recent findings have shown that the secretome of the IM-delivered MSCs enters the circulation and provides systemic effects on distant organs. In addition, muscle tissue provides a safe residence for the delivered MSCs and an extended secretorily active dwell time compared with other delivery routes. There are, however, controversies concerning the fate of MSCs post IM-delivery and, specifically, into an injured site with proinflammatory cues. This review seeks to provide a brief overview of the fate and efficacy of IM-delivered MSCs and to identify the gaps that require further assessment for adoption of this promising route in the treatment of systemic disease. Stem Cells Translational Medicine 2019;8:456-465.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.